Drug Shortage Report for CISPLATIN INJECTION
| Report ID | 98188 |
| Drug Identification Number | 02403188 |
| Brand name | CISPLATIN INJECTION |
| Common or Proper name | CISPLATIN INJECTION |
| Company Name | TEVA CANADA LIMITED |
| Active Ingredient(s) | CISPLATIN |
| Strength(s) | 1.0MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 50 & 100ml |
| ATC code | L01XA |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2019-11-07 |
| Estimated end date | 2020-01-31 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2019-11-29 |
| Company comments | Teva is allocating and covering 30% of the market |
| Health Canada comments | |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.